MarginsXMarginsX
Home › Markets › Health Care › GENB

Generate Biomedicines Inc. (GENB)

GENB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$10.49
-13.09% on the day
Market cap
$1.4B
Small cap
Revenue
New registrant: no annual report filed under this company yet
Net income
New registrant: no annual report filed under this company yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerGENB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2026
SEC CIK0002100782
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

New registrant: no annual report filed under this company yet.

Warning signs

Cash runway
7.0 months
$140.3M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$25.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"As of December 31, 2025, the Company had concluded that there was substantial doubt about its ability to continue as a going concern."
10-Q 2026-11-12
Cash and burn$140.3M cash; operating cash flow -$60.4M a quarter.Report 2026-09-30
Shares outstanding129,096,666 (2026-10-29).Cover page 2026-10-29
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-04
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $25.3M, sold $16K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$4.2M-$87.7M-$54.9M$140.3MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
$6.3M-$67.3M-$57.9M$135.4MNo debt tagsNeeds four quarters10-Q 2026-08-06
Q1 2026
2026-03-31
$7.2M-$61.4M-$80.4M$160.6MNo debt tagsNeeds four quarters10-Q 2026-05-07
Q3 2026
2025-09-30
$9.6M-$53.6M-$48.4M$118.5MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2025-06-30
$10.1M-$52.4M-$48.8M$154.3MNo debt tagsNeeds four quarters10-Q 2026-08-06
Q1 2026
2025-03-31
$8.8M-$41.7M-$53.2M$220.6MNo debt tagsNeeds four quarters10-Q 2026-05-07

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42026-02-27
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12

Source: SEC EDGAR submissions feed, 58 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-7.6%
1 month-1.5%
3 months-19.7%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-40.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NUVBNuvation Bio Inc.$3.84-3.76%$1.4B
ANABAnaptysBio Inc.$45.73-1.12%$1.4B
TYRATyra Biosciences Inc.$19.74-1.42%$1.4B
URGNUroGen Pharma Ltd.$28.10+7.33%$1.4B
GPCRStructure Therapeutics Inc.$18.57-7.15%$1.3B
AVLNAvalyn Pharma Inc.$29.76-1.72%$1.3B
OCULOcular Therapeutix Inc.$6.01-3.22%$1.3B
LBRXLB Pharmaceuticals Inc$42.99-0.05%$1.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier